CHICAGO - (Business Wire) Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include:
SAP AG (NYSE:
SAP),
BT Americas (NYSE:
BT),
Pacific Gas & Electric Company (NYSE:
PCG),
Alkermes, Inc. (Nasdaq:
ALKS) and
Eli Lilly (NYSE:
LLY).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579
Here are highlights from Wednesday’s Analyst Blog:
Integration Risks for SAP Remain
SAP AG (NYSE: SAP) reported in-line revenues and weaker-than-expected earnings in first quarter of 2008 due to the costs of the Business Objects [BOBJ] acquisition. The company continued its growth in Asia, the Americas and Europe. Additionally, the company proved it is still competitive with larger deals, winning BT Americas (NYSE: BT) and Pacific Gas & Electric Company (NYSE: PCG) during the first quarter.
However, we are now concerned about the integration risks related to the acquisition of BOBJ, and the drag this could have on management’s ability to run its core business as it tries to integrate BOBJ into the SAP fold. We are also concerned with the company’s change of stance on acquisitions. Thus, we continue to rate shares of SAP a Hold.
Pipeline Issues Keep ALKS a Hold
We are optimistic about a number of mid-to late-stage candidates of Alkermes, Inc. (Nasdaq: ALKS), despite the termination of the AIR Insulin program being a major blow to its clinical pipeline. However, the latest we expect to see one of these candidates on the market is in 2010.
Termination of the AIR Insulin program by Eli Lilly (NYSE: LLY) will see revenues of Alkermes declining by over 11 percent in fiscal 2009. We believe the company will need to cut down on its research and development funding while simultaneously engaging in share repurchases of at least 5 million shares annually after fiscal 2010, if it aims to achieve its goal of an EPS of $2.00 - $3.00 in 2013.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks.com
Mark Vickery
Web Content Editor
312-265-9380
Visit: www.zacks.com
